Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics (NASDAQ:ARTV), sold 7,002 shares on May 19, 2026. The transaction totaled $63,072.
Shares were sold at prices ranging from $8.7421 to $9.0104, with a weighted average of $9.0078. The sales were automatic to cover tax withholding obligations.
Artiva shares closed at $8.55, down 18.6% over the past week. However, the stock surged 296% over the past year and 170% in the last six months.
After the sale, Horan directly holds 293,450 shares.
According to Bond.az analysis, the stock appears overvalued based on fair value.
In other news, Artiva will present clinical data on AlloNK therapy combined with rituximab at the EULAR Congress. Data from 31 patients showed 71% of refractory rheumatoid arthritis patients achieved ACR50 response.
Artiva appointed Diego Miralles, M.D., as President and Head of R&D. H.C. Wainwright raised its price target to $35, maintaining a Buy rating.
